ArticleTranslational gastroenterology and hepatology2025
The prognostic impact of statin exposure in metabolic dysfunction-associated steatotic liver disease: a cohort study.
Article in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing global health concern associated with metabolic syndromes such as obesity and type 2 diabetes. While statins are widely used to manage hypercholesterolemia, their potential protective effects against liver-related outcomes in MASLD have not been thoroughly explored. This study aims to evaluate the prognostic impact of statin use on clinical outcomes, including mortality, hepatocellular carcinoma (HCC) incidence, and hepatic decompensation, in patients with MASLD. Methods: This study investigates the impact of statin use on outcomes in patients with MASLD. A population-based study cohort was analyzed using data from the UK Biobank, which included 402,476 participants after exclusions. Inverse probability of treatment weighting (IPTW) was utilized to balance baseline characteristics. The primary outcomes included all-cause mortality and liver-related mortality, with secondary outcomes covering the incidence of HCC and hepatic decompensation. Subgroup analyses were conducted to assess the effects of specific statin types and gender differences. Results: Statin use correlated with a 19% reduction in all-cause mortality and a 37% reduction in liver-related mortality in the MASLD cohort. Notably, atorvastatin was significantly effective in reducing all-cause mortality, liver-related mortality, hepatic decompensation, and HCC risk. Gender-specific analyses demonstrated that female statin users experienced the most significant reductions in mortality and HCC incidence. Statin use significantly improved survival and decreased liver-related outcomes in MASLD patients, with gender-specific analyses showing enhanced effects for female users. Conclusions: The findings suggest the importance of statin selection and highlight that gender-specific strategies may enhance treatment efficacy in the MASLD cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.